- Home
- API vs LXEO Comparison
API vs LXEO Comparison
Compare API & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | API | LXEO |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.9M | 369.8M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | API | LXEO |
|---|---|---|
| Price | $4.12 | $4.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 449.0K | ★ 667.0K |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $12.87 | N/A |
| P/E Ratio | $92.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $2.72 |
| 52 Week High | $5.15 | $10.99 |
Technical Indicators
Market Signals| Indicator | API | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 40.40 |
| Support Level | $4.01 | $4.95 |
| Resistance Level | $4.29 | $5.11 |
| Average True Range (ATR) | 0.20 | 0.37 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 69.89 | 28.32 |
Price Performance
Historical ComparisonAbout API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.